{"url_path":"/sec/inti/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","accession_number":"0001493152-26-023622","cik":"0001042418","ticker":"INTI","issuer_name":"Inhibitor Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","primary_entity_key":"0001042418","primary_entity_name":"Inhibitor Therapeutics, Inc."},"word_count":259,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors.**\n\n \n\nInvesting\nin our common stock is highly speculative and involves a high degree of risk. Before purchasing our common stock, you should carefully\nconsider the following risk factors, those risks included in “Part I, Item 1A, Risk Factors” in our 2025 Annual Report, together\nwith all of the other information contained in this Quarterly Report, including our unaudited condensed financial statements and the\nrelated notes appearing elsewhere in this Quarterly Report.\n\n \n\n**Uncertainty\nrelating to the pending securities purchase agreement and related litigation could adversely affect our liquidity and business operations.**\n\n** **\n\nIn\nFebruary 2026, we entered into a securities purchase agreement with an institutional investor providing for aggregate gross proceeds\nof approximately $3.0 million. As of the date of this Quarterly Report, the transaction has not been consummated, and we have initiated\nlitigation relating to the investor’s alleged failure to fulfill its obligations under the agreement.\n\n \n\nThere\ncan be no assurance regarding the timing or outcome of the litigation, whether the transaction will ultimately close, or whether we will\nreceive any proceeds under the agreement. The uncertainty associated with the pending transaction and related legal proceedings may adversely\naffect our liquidity, financial condition and ability to fund our operations and development activities. In addition, such uncertainty\nmay negatively impact our ability to obtain additional capital, enter into strategic transactions or maintain relationships with existing\nand prospective investors, vendors and collaborators.\n\n \n\nIf\nwe are unable to obtain sufficient funding on acceptable terms, we may be required to delay, reduce or discontinue certain operational,\nregulatory or development activities."}